The Use of Saquinavir/Ritonavir 1000/100 Mg Twice Daily in Patients with Tuberculosis Receiving Rifampin

Lucas S.B. , Hounnou A. , Peacock C. , Beaumel A. , Djomand G. , N'Gbichi J.M. , Yeboue K. , Honde M. , Diomande M. , & Giordano C. The mortality and pathology of HIV infection in a west African city. AIDS 1993; 7: 1569–1579.

Burman W.J. , Gallicano K. , & Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clinical Infectious Diseases 1999; 28: 419–429.

British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary No. 46. 2003.

Lopez-Cortes L.F. , Ruiz-Valderas R. , Viciana P. , Alarcon-Gonzalez A. , Gomez-Mateos J. , Leon-Jimenez E. , Sarasanacenta M. , Lopez-Pua Y. , & Pachon J. Pharmacokinetic interactions between efavirenz and rifampin in HIV-infected patients with tuberculosis. Clinical Pharmacokinetics 2002; 41: 681–690.

Ribera E. , Pou L. , Lopez R.M. , Crespo M. , Falco V. , Ocana I. , Ruiz I. , & Pahissa A. Pharmacokinetic interaction between nevirapine and rifampin in HIV-infected patients with tuberculosis. Journal of Acquired Immune Deficiency Syndromes 2001; 28: 450–453.

Veldkamp A.I. , Hoetelmans R.M. , Beijnen J.H. , Mulder J.W. , & Meenhorst P.L. Ritonavir enables combined therapy with rifampin and saquinavir. Clinical Infectious Diseases 1999; 29: 1586.

Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Morbidity & Mortality Weekly Reports 2000; 49: 185–189.

Centers for Disease Control and Prevention. Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors. 2004. http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/TOC.htm.

Dragsted U.B. , Gerstoft J. , Pedersen C. , Peters B. , Duran A. , Obel N. , Castagna A. , Cahn P. , Clumeck N. , Bruun J.N. , Benetucci J. , Hill A. , Cassetti I. , Vernazza P. , Youle M. , Fox Z. , & Lundgren J.D. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. Journal of Infectious Diseases 2003; 188: 635–642.

Youle M. , Gerstof J. , Fox Z. , Losso M. , Jayaweera D.T. , Rieger A. , Castagna A. , Walmsley S. , Hill A. , Dragstead U.B. , & Lundgren J.D. The final week 48 of a phase IV randomized, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: the MaxCmin2 trial. 2nd International AIDS Society Conference on HIV Pathogenesis & Treatment. 13–16 July 2003, Paris, France. Abstract LB23.

Buss N. , Snell P. , Bock J. , Hsu A. , & Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. British Journal of Clinical Pharmacology 2001; 52: 255–264.

Gerstoft J. , Kirk O. , Obel N. , Pedersen C. , Mathiesen L. , Nielsen H. , Katzenstein T.L. , & Lundgren J.D. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003; 17: 2045–2052.

Gulick R.M. , Ribaudo H.J. , Shikuma C.M. , Lustgarten S. , Meyer W.A. , Klingman K. , Squires K.E. , Snyder S. , & Kuritzkes D.R. ACTG 5095: a comparative study of 3 protease inhibitor sparing antiretroviral regimens for the initial treatment of HIV infection. 2nd International AIDS Society Conference on HIV Pathogenesis & Treatment. 13–16 July 2003, Paris, France. Abstract 41.

Gallant J.E. , Rodriguez A.E. , Weinberg W. , Young B. , Berger D. , Lim M.L. , Liao Q. , Ross L. , Johnson J. , & Shaffer M.S. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14–17 September 2003, Chicago, USA. Abstract H-1722a.